Loading…
Pacific Biosciences of California, Inc. is projected to rise to $1.84 by 2027, a +18% move from its current price of $1.56. PACB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.49 | $1.56 | $1.63 | -0.08% |
| Jul 15 | $1.47 | $1.56 | $1.65 | -0.16% |
| Jul 16 | $1.45 | $1.56 | $1.67 | -0.23% |
| Jul 17 | $1.43 | $1.56 | $1.69 | -0.31% |
| Jul 18 | $1.42 | $1.55 | $1.71 | -0.39% |
| Jul 19 | $1.40 | $1.55 | $1.72 | -0.47% |
| Jul 20 | $1.39 | $1.55 | $1.73 | -0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.39 | $1.55 | $1.73 | -0.54% |
| Week 2 | $1.32 | $1.54 | $1.80 | -1.08% |
| Week 3 | $1.27 | $1.53 | $1.86 | -1.62% |
| Week 4 | $1.22 | $1.53 | $1.90 | -2.16% |
| Week 5 | $1.19 | $1.52 | $1.94 | -2.69% |
| Week 6 | $1.15 | $1.51 | $1.98 | -3.22% |
| Week 7 | $1.12 | $1.50 | $2.01 | -3.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies.
The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data.
The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
PACB is a healthcare company focused on sequencing technologies and related consumables, systems, and workflow solutions. The stock currently trades at $1.56 per share and has a market capitalization of $484.54M, with a market rank of 3079. The forecasted path shows long‑term upside, with average prices rising from 2026 onward toward substantially higher levels by 2050.
A major floor 29.1% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
The nearest ceiling, 11.5% above — a clean break opens room to run.
A major ceiling 26.1% above — clearing it would confirm fresh momentum.
Key PACB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PACB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.58 | Sell | $1.58 | Sell |
| MA 10 | $1.64 | Sell | $1.58 | Sell |
| MA 20 | $1.51 | Buy | $1.54 | Buy |
| MA 50 | $1.45 | Buy | $1.50 | Buy |
| MA 100 | $1.47 | Buy | $1.53 | Buy |
| MA 200 | $1.71 | Sell | $1.60 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.49 | Neutral |
| Stoch RSI (14) | 35.67 | Neutral |
| CCI (20) | 25.68 | Neutral |
| Williams %R (14) | -41.86 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 19.08 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 58.14 | Neutral |
| TRIX (15) | 0.53 | Buy |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 45.10 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 1.52 | Buy |
| ADX (14) | 15.93 | Neutral |
| ATR (14) | 0.06 | Info |
Technical outlook for the near term shows bullish sentiment. RSI14 is 50, with a 50-day simple moving average of $1.45 and a 200-day simple moving average of $1.70. Near-term support is at $1.22 and resistance at $1.74. The 30‑day price range spans $1.18 to $2.06, framing a constructive setup despite the current price near the lower end of the range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $1.56 | $1.79 | 0% | Neutral | |
| $1.39 | $1.84 | $2.61 | +18% | Neutral | |
| $1.56 | $2.16 | $3.23 | +39% | Bullish | |
| $1.74 | $2.51 | $3.90 | +61% | Bullish | |
| $1.95 | $2.90 | $4.67 | +86% | Bullish | |
| $1.80 | $2.76 | $4.57 | +77% | Bullish | |
| $1.85 | $2.93 | $4.99 | +88% | Bullish | |
| $1.86 | $3.03 | $5.28 | +94% | Bullish | |
| $1.87 | $3.13 | $5.57 | +100% | Bullish | |
| $2.58 | $4.43 | $8.04 | +184% | Bullish | |
| $2.65 | $5.14 | $10.12 | +229% | Bullish | |
| $5.29 | $11.75 | $26.02 | +653% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.12 | $1.56 | $1.82 | +0.00% |
| August 2026 | $1.20 | $1.43 | $1.77 | -8.25% |
| September 2026 | $1.20 | $1.45 | $1.83 | +1.52% |
| October 2026 | $1.18 | $1.44 | $1.84 | -0.96% |
| November 2026 | $1.10 | $1.36 | $1.75 | -5.83% |
| December 2026 | $1.10 | $1.37 | $1.79 | +0.96% |
Click any year to see its month-by-month PACB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PACB to range from $1.12 to $1.79 through 2026. The $1.56 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The PACB price prediction for 2027 points to an average of $1.84 (low $1.39, high $2.61) — a potential gain of +18% on today's $1.56. Price action looks broadly range-bound.
In 2028, PACB is projected to trade between $1.56 and $3.23, averaging $2.16 — a potential gain of +39% from today's $1.56. That is up +18% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Pacific Biosciences of California, Inc.'s 2029 outlook centres on $2.51, within a $1.74 to $3.90 range. That is up +16% on the projected 2028 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2030, PACB could reach as high as $4.67, with a base case around $2.90 and support toward $1.95 — roughly +86% from $1.56. Buyers look set to stay in control over this stretch.
Expect PACB to range from $1.80 to $4.57 through 2031. The $2.76 average target implies a +77% move from current prices. That is -5% versus the projected 2030 average. Momentum favours further upside here.
The PACB price prediction for 2032 points to an average of $2.93 (low $1.85, high $4.99) — a potential gain of +88% on today's $1.56. Buyers look set to stay in control over this stretch.
In 2033, PACB is projected to trade between $1.86 and $5.28, averaging $3.03 — a potential gain of +94% from today's $1.56. That is up +3% on the projected 2032 average. Momentum favours further upside here.
Pacific Biosciences of California, Inc.'s 2034 outlook centres on $3.13, within a $1.87 to $5.57 range. That is up +3% on the projected 2033 average. That marks a +100% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, PACB could reach as high as $8.04, with a base case around $4.43 and support toward $2.58 — roughly +184% from $1.56. Momentum favours further upside here.
Expect PACB to range from $2.65 to $10.12 through 2040. The $5.14 average target implies a +229% move from current prices. That is up +16% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The PACB price prediction for 2050 points to an average of $11.75 (low $5.29, high $26.02) — a potential gain of +653% on today's $1.56. Momentum favours further upside here.
Investing $1,000 in PACB today (≈ 641.025641 PACB) could be worth
$7,530.93
+$6,530.93 (+653%) by 2050 · US Dollar
Based on the average projected PACB price of $11.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PACBwould be worth at today's price.
$1,000 invested in PACB on Jul 10, 2025 (≈ 666.666667 PACB) would be worth
$1,040
+$40 (+4.0%) today · 1.04× · US Dollar
Based on a PACB entry price of $1.5 vs. today's $1.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.68 | $928.57 | -7.1% |
| 1 month ago | $1.37 | $1,138.69 | +13.9% |
| 3 months ago | $1.34 | $1,164.18 | +16.4% |
| 6 months ago | $2.01 | $776.12 | -22.4% |
| 1 year ago | $1.5 | $1,040 | +4.0% |
| All time (5.0y) ago | $27.56 | $56.6 | -94.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PACB forecast.
Our base-case forecast reaches $3.10 around 2034.
Implied market cap at $3.10: $962.87M
The multi‑year forecast presents a clear path of upside, with 2026’s avg price at $1.56 and 2027 at $1.85, rising to $2.16 in 2028 and $2.52 in 2029. By 2030 the avg is $2.91 (ROI 86.7%), and it remains bullish through 2031 ($2.76), 2032 ($2.95), 2033 ($3.04), and 2034 ($3.14). The 2035 forecast shows a stronger move with an avg of $4.49 (ROI 187.8%) and a max of $8.16.
In the longer horizon, 2040 carries an avg of $5.13 (ROI 228.8%) and a max of $10.12, while 2050 reaches an avg of $11.93 (ROI 664.5%) with a max of $26.43. These figures indicate meaningful upside but remain estimates, not guarantees, and should be weighed with appropriate uncertainty and risk.
Tap a question to reveal the answer.
2030 forecast: min $1.96, avg $2.91, max $4.69; ROI 86.7%; sentiment BULLISH.
Forecasts show rising averages from 2026 onward, with 2030 avg $2.91 (ROI 86.7%), 2040 avg $5.13 (ROI 228.8%), and 2050 avg $11.93 (ROI 664.5%). These are estimates, not guarantees.
Yes. The 2040 forecast max is $10.12 and the 2050 max is $26.43, indicating possible movement above $10 in the longer term.
Current price is $1.56. The 30‑day range runs from $1.18 to $2.06.
Market cap is $484.54M and the rank is 3079.
Pacific Biosciences of California, Inc. Community Discussion
0Share your Pacific Biosciences of California, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.